VivoSim Labs (NASDAQ:VIVS) Issues Earnings Results

VivoSim Labs (NASDAQ:VIVS) announced its quarterly earnings data on Thursday. The company reported ($0.03) EPS for the quarter, FiscalAI reports. VivoSim Labs had a negative net margin of 11,016.07% and a negative return on equity of 612.23%. The firm had revenue of $0.05 million for the quarter.

VivoSim Labs Trading Down 10.8%

NASDAQ VIVS traded down $0.02 during trading on Thursday, hitting $0.14. 1,614,603 shares of the company’s stock were exchanged, compared to its average volume of 2,350,676. The company has a market cap of $2.29 million, a PE ratio of -0.03 and a beta of 1.58. VivoSim Labs has a fifty-two week low of $0.12 and a fifty-two week high of $3.40. The stock’s 50 day moving average price is $0.20 and its two-hundred day moving average price is $1.00.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VivoSim Labs in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, VivoSim Labs presently has a consensus rating of “Sell”.

About VivoSim Labs

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds.